Rare gene mutation lets some people thrive on just 4 hours of sleep
Doctors recommend at least seven to nine hours of bedtime each night, with sleep deprivation linked to early onset of conditions like Alzheimer's and heart disease.
However, people with this rare mutation tend to feel fully rested after only four to six hours of sleep each night, without showing any of the adverse effects linked to chronic sleep loss.
Such people have less need for sleep, as measured using the low-frequency Delta brain waves on EEG scans, and may also feel 'worse' if they sleep more, say researchers from the Chinese Academy of Sciences.
Until now, four genes have been linked to such a natural short sleep, or NSS, in people.
Previous studies have revealed that a phosphate molecule exchange process at the junction of two connecting nerve cells plays a critical role in the sleep-wake cycle.
Researchers have now found that a mutation in people with NSS, within the gene salt-induced kinase 3 (SIK3), also plays a key role in human sleep duration.
A mutation called N783Y was found to alter the SIK3 protein's structure, hindering its ability to engage in the phosphate molecule transfer process.
In this mutation, the asparagine (N) amino acid in the SIK3 protein's 783rd protein building block position is replaced by the molecule tyrosine (Y).
When scientists created mice with this N783Y mutation, the mutant mice were found to sleep an average of 30 minutes less each night, compared with unaltered mice.
Further analysis confirmed that the mutation caused structural changes affecting the protein's ability to transfer key phosphate molecules to other proteins.
The mutation did not seem to affect the levels of proteins in the mice, indicating that the sleep duration changes are linked to altered SIK3 activity and not to protein quantity within the rodents.
It also led to a slight increase in EEG delta power, indicating that people with the mutation experience more deep sleep.
With the study, scientists have confirmed the critical role played by the SIK3 gene in regulating human sleep duration, indicating it could be a promising target for sleep drugs.
They hope to conduct further studies to gain more insight into how some enzymes linked to the process regulate sleep.
The research may lead to potential new drug targets to improve sleep, researchers say.
'These findings advance our understanding of the genetic underpinnings of sleep,' scientists wrote, adding that it provides 'further support for potential therapeutic strategies to enhance sleep efficiency'.
The Independent
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
2 days ago
- Gulf Today
Ancient ritual that could help improve your sleep
Storm Newton, The Independent An ancient ritual involving the forceful blowing of a conch shell could offer a surprising, non-invasive treatment for a widespread sleep disorder, according to new research. Known as shankh blowing, the practice involves a deep inhalation followed by a powerful exhalation into the spiral-shaped shell of a sea snail. Researchers suggest this technique could significantly improve sleep for individuals suffering from obstructive sleep apnoea (OSA), potentially negating the need for cumbersome medical equipment. Obstructive sleep apnoea, which affects an estimated eight million people in the UK, occurs when the throat muscles relax and narrow during sleep, leading to symptoms such as loud snoring, choking noises, and frequent awakenings. The findings stem from a small trial conducted in India, involving 30 participants aged between 19 and 65, all diagnosed with OSA. For the trial, 16 people were provided with a traditional shankh used in yogic practices and trained in how to use it properly before taking it home, while the remaining 14 people were asked to carry out deep breathing exercises. Both groups were encouraged to practice for a minimum of 15 minutes five days a week. They were monitored during sleep and asked questions about sleep quality and how tired they felt during the day. After six months, the study found those who practised shankh blowing reported sleeping better and were 34 per cent less sleepy during the day. They also had higher levels of oxygen in the blood during the night and had four to five fewer apnoeas, where breathing stops during sleep, per hour on average. They also had higher levels of oxygen in their blood during the night. Dr Krishna K Sharma, of the Eternal Heart Care Centre and Research Institute in Jaipur, India, said: "The way the shankh is blown is quite distinctive. "It involves a deep inhalation followed by a forceful, sustained exhalation through tightly pursed lips. "This action creates strong vibrations and airflow resistance, which likely strengthens the muscles of the upper airway, including the throat and soft palate, areas that often collapse during sleep in people with OSA. "The shankh's unique spiralling structure may also contribute to specific acoustic and mechanical effects that further stimulate and tone these muscles." Continuous positive airway pressure (Cpap) machines are the first line of treatment for OSA. They involve patients wearing a mask that blows pressurised air into the nose and throat while they sleep. However, they can be uncomfortable. Speaking of Cpap, Dr Sharma said: "While effective, many patients find it uncomfortable and struggle to use it consistently." He suggests shankh blowing could be a "promising alternative". "Shankh blowing is a simple low-cost, breathing technique that could help improve sleep and reduce symptoms without the need for machines or medication," Dr Sharma said. Researchers are now planning a larger trial involving several hospitals. Dr Sharma added: "This next phase will allow us to validate and expand on our findings in a broader, more diverse population and assess how shankh blowing performs over longer periods. "We also want to study how this practice affects airway muscle tone, oxygen levels and sleep in greater detail. "We're particularly interested in comparing shankh blowing with standard treatments like Cpap, and in examining its potential help in more severe forms of OSA." Reacting to the findings, Professor Sophia Schiza, head of the ERS group on sleep disordered breathing, based at the University of Crete, Greece, said: "We know that OSA patients have poor quality of sleep, and higher risks of high blood pressure, strokes and heart disease. "A proportion of patients experience sleepiness during the day. "While Cpap and other treatments are available based on careful diagnosis of disease severity, there is still need for new treatments. "This is an intriguing study that shows the ancient practice of shankh blowing could potentially offer an OSA treatment for selected patients by targeting muscles training. 'A larger study will help provide more evidence for this intervention which could be of benefit as a treatment option or in combination with other treatments in selected OSA patients.'
Gulf Today
6 days ago
- Gulf Today
Doctors decry RFK Jr decision to slash vaccine grants
Julia Musto, The Independent Doctors are sounding the alarm about potentially deadly consequences of the Donald Trump administration's decision to slash $500 million in funding for mRNA vaccine development, saying the "deeply troubling" move could leave Americans defenceless in the face of a biological attack, or another pandemic. Leading physicians and vaccine specialists were among the medical and scientific experts who told The Independent that years of progress had been lost, including the lessons learned during Covid. "This is a deeply troubling development that will, in the short term, leave the US poorly prepared for a pandemic or biological attack, and, in the long term, stifle medical innovation upon which so many Americans depend for life saving cures," Dr. Jennifer Nuzzo, director of the Pandemic Center at the Brown University School of Public Health, said in an email. Health and Human Services Sec. Robert F Kennedy Jr announced on Tuesday the termination of 22 projects, including contracts with Emory University and Covid shot-makers Moderna, Pfizer, and AstraZeneca. "We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate," Kennedy said. While Kennedy, who has questioned Covid vaccine safety and previously falsely claimed the measles vaccine contains foetal debris, cited a review of "the science" in terminating the project. But Dr Nuzzo said the "attack on mRNA vaccine technology rests on phony and false claims, proven so by real facts and evidence". She continued: "It is, however, aligned with his long-held and deadly determination to sow doubts about all vaccines and to restrict the ability of the American people to access vaccines. Our nation will pay dearly for this decision in dollars and lives." The mRNA vaccines work differently from traditional vaccines, which inject a weakened virus into the body to trigger an immune response. Instead, mRNA vaccines teach the cells to make small and harmless pieces of virus that trigger the same response. The anti-vaxxer movement and Kennedy have inaccurately claimed that mRNA Covid vaccines are deadly and that vaccines "poisoned" American children but they are safe according to decades of public research and countless government assessments. The only mRNA vaccines currently available are Covid vaccines. They were able to be brought to market so quickly because scientists didn't need the virus to make them, and the vaccine material can be created in a lab. Research also has been underway to produce mRNA vaccines against cancer and other infectious diseases, work that has been going on for decades. "While most would associate mRNA vaccine technology with Covid, it was in development for over half a century and the US government's partnership in that development goes back decades," Richard Hughes IV, a former vice president of public policy at mRNA vaccine manufacturer Moderna who teaches vaccine law at George Washington University Law School, told The Independent. "These kinds of partnerships are what drive innovation and save us from public health emergencies. When we lose this kind of progress, we create future public health risks." Scientists know it's only a matter of time before the next pandemic, when vaccines may once again be needed en masse. Dr. Jake Scott, an infectious diseases physician and Clinical Associate Professor at Stanford University School of Medicine, said that no other vaccine technology could provide the world with a vaccine as quickly as is need during a pandemic. He noted that Kennedy's decision was rewriting the history of the pandemic and the lifesaving track record of mRNA vaccines. "Vaccines aren't some niche drug. We're not talking about some rare skin cancer drug. We're talking about medicines that apply to literally every human being on the planet and we should have learned from the Covid pandemic that everyone is potentially susceptible to pandemic," Dr Scott said. In what experts have labelled an assault on science, the Trump administration has eliminated grants and dramatically reduced the workforce of federal health and science agencies. Theses actions, and Kennedy's mRNA cuts, are likely in response to government vaccine mandates and restrictions, Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, told The Independent.
Al Etihad
7 days ago
- Al Etihad
Harvard research on reversing Alzheimer's reveals lithium as potential key
6 Aug 2025 22:51 ABU DHABI (ALETIHAD)A decade of investigation by scientists at Harvard Medical School have revealed that the loss of the metal lithium plays a powerful role in Alzheimer's disease, a finding that could lead to earlier detection and new treatments for the disease that affects memory and cognitive led by Bruce A. Yankner, professor of genetics and neurology at Harvard Medical School, reported that they were able to reverse the disease in mice and restore brain function with small amounts of the compound lithium orotate, enough to mimic the metal's natural level in the brain. Their study appeared Wednesday in the journal findings are based on a series of experiments in mice and on analyses of human brain tissue and blood samples from individuals in various stages of cognitive scientists found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, similar lithium depletion accelerated brain pathology and memory team further found that reduced lithium levels stemmed from binding to amyloid plaques and impaired uptake in the brain. In a final set of experiments, the team found that a novel lithium compound that avoids capture by amyloid plaques restored memory in mice. The results unify decades-long observations in patients, providing a new theory of the disease and a new strategy for early diagnosis, prevention, and an estimated 400 million people worldwide, Alzheimer's disease involves an array of brain abnormalities — such as clumps of the protein amyloid beta, neurofibrillary tangles of the protein tau, and loss of a protective protein called REST — but these never explained the full story of the instance, some people with such abnormalities show no signs of cognitive decline. And recently developed treatments that target amyloid beta typically don't reverse memory loss and only modestly reduce the rate of decline. It is also clear that genetic and environmental factors affect risk of Alzheimer's, but scientists haven't figured out why some people with the same risk factors develop the disease while others do not. Lithium, the study authors said, may be a critical missing link.'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' said senior author Bruce Yankner, professor of genetics and neurology in the Blavatnik Institute at HMS, who in the 1990s was the first to demonstrate that amyloid beta is study raises hopes that researchers could one day use lithium to treat the disease in its entirety rather than focusing on a single facet such as amyloid beta or tau, he of the main discoveries in the study is that as amyloid beta begins to form deposits in the early stages of dementia in both humans and mouse models, it binds to lithium, reducing lithium's function in the brain. The lower lithium levels affect all major brain cell types and, in mice, give rise to changes recapitulating Alzheimer's disease, including memory authors identified a class of lithium compounds that can evade capture by amyloid beta. Treating mice with the most potent amyloid-evading compound, called lithium orotate, reversed Alzheimer's disease pathology, prevented brain cell damage, and restored the findings need to be confirmed in humans through clinical trials, they suggest that measuring lithium levels could help screen for early Alzheimer's. Moreover, the findings point to the importance of testing amyloid-evading lithium compounds for treatment or lithium compounds are already used to treat bipolar disorder and major depressive disorder, but they are given at much higher concentrations that can be toxic, especially to older team found that lithium orotate is effective at one-thousandth that dose — enough to mimic the natural level of lithium in the brain. Mice treated for nearly their entire adult lives showed no evidence of lithium has not yet been shown to be safe or effective in protecting against neurodegeneration in humans, Yankner emphasises that people should not take lithium compounds on their own. But he expressed cautious optimism that lithium orotate or a similar compound will move forward into clinical trials in the near future and could ultimately change the story of Alzheimer's treatment. 'My hope is that lithium will do something more fundamental than anti-amyloid or anti-tau therapies, not just lessening but reversing cognitive decline and improving patients' lives,' he said. Source: Aletihad - Abu Dhabi
